

## Claims

- 1) Use of adeno-associated viruses for lowering the radiotherapy-induced or chemotherapy-induced resistance in patients who suffer from a cancer which is to be treated by radiotherapy or chemotherapy.
- 2) Use according to claim 1, wherein the adeno-associated viruses are used in a dose of  $10^9$ - $10^{10}$  AAV particles/kg body weight.
- 3) Use according to any of claims 1 to 2, wherein the adeno-associated virus is adeno-associated virus 2 (AAV-2).
- 4) Use according to any of claims 1 to 3, wherein the cancer to be treated by radiotherapy or chemotherapy is a colon cancer, pancreatic carcinoma or brain tumor or small cell lung carcinoma.
- 5) Use according to any of claims 1 to 4, wherein the use is made intravenously, cutaneously, orally or intratumorally.
- 6) Use according to any of claims 1 to 5, wherein the use is made before, after or simultaneously with a chemotherapy or radiotherapy.

SUB  
B1

- 7) A pharmaceutical composition containing a chemotherapeutic agent and adeno-associated viruses.
- 8) The pharmaceutical composition according to claim 7, wherein the chemotherapeutic agent is cisplatin and/or etoposide.
- 9) The pharmaceutical composition according to claim 7 or 8, wherein it is an injection or infusion solution, an aerosol spray or an ointment.

SUB  
B1  
CON4.

ADD  
B2 → add c4

6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100